Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 263 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: rhuFab V2 (ranibizumab) Clear all
Completed Phase 2 Interventional

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).

NCT00713518
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
San Francisco, California • Fort Myers, Florida • Winter Haven, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

Ranibizumab for the Inhibition of Neovascularization in Pterygia

NCT00768963
View directory record Official record
Conditions
Pterygium
Interventions
ranibizumab
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 10, 2026, 1:46 PM EDT
Completed No phase listed Observational

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

NCT05146687
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Aflibercept, Ranibizumab, Bevacizumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
369,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 10, 2026, 1:46 PM EDT
Not listed Phase 2Phase 3 Interventional

Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients

NCT02296567
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Ranibizumab, Bevacizumab, Aflibercept, Control Group
Drug · Other
Lead sponsor
East Florida Eye Institute
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stuart, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)

NCT01552408
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion

NCT00815360
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
intravitreal injection of ranibizumab, peripheral laser, intravitreal injection of triamcinolone acetonide, macular laser
Drug · Procedure
Lead sponsor
Retina Associates of Florida, P.A.
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)

NCT01445899
View directory record Official record
Conditions
Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II)
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
20
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 10, 2026, 1:46 PM EDT
Completed No phase listed Observational

Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)

NCT02420132
View directory record Official record
Conditions
Macular Edema, Macular Degeneration
Interventions
Ranibizumab
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 10, 2026, 1:46 PM EDT
Not listed Phase 3 Interventional

Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD

NCT02727881
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Squalamine lactate ophthalmic solution, 0.2%, Placebo Ophthalmic solution, ranibizumab
Drug
Lead sponsor
Ohr Pharmaceutical Inc.
Industry
Eligibility
50 Years to 110 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
118
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 10, 2026, 1:46 PM EDT
Completed No phase listed Observational

Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab

NCT02000102
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Intravitreal Injection of Aflibercept
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 10, 2026, 1:46 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

NCT01944839
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
E10030, ranibizumab, E10030 sham intravitreal injection
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 10, 2026, 1:46 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)

NCT01025232
View directory record Official record
Conditions
Age Related Macular Degeneration, Choroidal Neovascular Membrane, Subfoveal Neovascular Age-Related Macular Degeneration, Macular Degeneration, Wet Age-Related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
50 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
2
States / cities
Houston, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 4 Interventional

Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment

NCT00680498
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Ranibizumab, Ranibizumab plus Photodynamic therapy
Drug
Lead sponsor
Illinois Retina Associates
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Oak Park, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration

NCT00805233
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
combination ranibizumab + bromfenac, ranibizumab injection alone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 10, 2026, 1:46 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)

NCT00538538
View directory record Official record
Conditions
Retinal Hemorrhage, Macular Degeneration
Interventions
vitrectomy with subretinal lucentis
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
50 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 10, 2026, 1:46 PM EDT
Withdrawn Phase 2 Interventional

Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids

NCT00846625
View directory record Official record
Conditions
Macular Edema, Uveitis
Interventions
triamcinolone, ranibizumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Dosing Interval of Higher Doses of Ranibizumab

NCT00533520
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
ranibizumab
Drug
Lead sponsor
Brandon G. Busbee, MD
Other
Eligibility
50 Years to 95 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 10, 2026, 1:46 PM EDT
Not listed Phase 3 Interventional

Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy

NCT01255774
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
51 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Oct 10, 2026, 1:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lucentis for Treatment of Macular Edema

NCT00464581
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Not listed
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
Up to 90 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Results available

Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema

NCT02471651
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration

NCT01926977
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Ranibizumab 0.5mg, Aflibercept 2.0mg
Drug
Lead sponsor
Arshad Khanani
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

NCT02022540
View directory record Official record
Conditions
Age-Related Macular Degeneration (AMD)
Interventions
PAN-90806 Ophthalmic Solution, Lucentis
Drug
Lead sponsor
PanOptica, Inc.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Colorado Springs, Colorado • Winter Haven, Florida • Shawnee Mission, Kansas + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

NCT03150589
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
SB11 (Proposed ranibizumab biosimilar), Lucentis (ranibizumab)
Drug
Lead sponsor
Samsung Bioepis Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
19
States / cities
Poway, California • Colorado Springs, Colorado • Fort Myers, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)

NCT00931489
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab (Lucentis(R))
Drug
Lead sponsor
Lawrence S. Morse, MD
Other
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 10, 2026, 1:46 PM EDT